Collaborations maximise the translation of UCL’s biomedical science
The TIN concept has been piloted with the Cell, Gene & Regenerative Medicine (CG&RM) community which has benefited from having a dedicated coordinator to galvanise and support the community. The impact of the initial work performed by the CG&RM TIN has been as a catalyst across UCL and our partner hospitals, linking up bioengineering with SLMS/BRC academics and clinicians to solve challenges in manufacturing and clinical delivery.
In addition it has raised the profile internally to recognise the collective international standing of our researchers in this field (UCL and our partner NHS Trusts participate in 34 out of 58 of all open UK advanced therapy trials i.e. 59%), competing with US institutions such as Harvard (55 trials), U.Penn (48 trials) as well as countries in Europe, France (47 trials), Germany (42 trials) and Spain (38 trials). The early focus of the coordinator was to map the UCL and partner hospital CG&RM landscape in terms of centres of excellence in research and clinical activity, physical facilities, funding, portfolio analysis, etc. The information gathered to date contributed to the development of a cross cutting themes in CG&RM that is common to all three UCL NIHR BRCs (UCLH, GOSH and Moorfields).
The community has now had several events organised, linking engineers with clinicians, showcasing individual projects as well as some of the commercial successes highlighting the support available through UCLB, TRO, CTU etc.
We now wish to maintain this level of support and expand to other therapeutic modalities.
Cell, Gene & RegMed TIN led pan-London analysis (2017) of future demand for GMP manufacturing.